查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1637030

重症肌无力治疗市场 - 全球产业分析、规模、占有率、成长、趋势及 2032 年预测

Myasthenia Gravis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032
出版日期: | 出版商: Fairfield Market Research | 英文 230 Pages | 商品交期: 2-5个工作天内

价格
简介目录

全球重症肌无力 (MG) 治疗市场预计将显着成长，复合年增长率为 8.2%。预计市场规模将从 2025 年的 26.9 亿美元飙升至 2032 年的 46.7 亿美元。这种上升趋势是由治疗技术的进步和对重症肌无力的认识的提高所推动的。

重症肌无力 (MG) 是一种神经肌肉自体免疫疾病，由于神经和肌肉之间的交流受损而导致肌肉无力和疲劳。治疗的主要目标是增强神经肌肉传递和抑制自体免疫活动。可用的治疗策略包括乙酰胆碱酯酶抑制剂、免疫抑制剂和创新单株抗体疗法。

重症肌无力盛行率不断上升（尤其是在老年族群）以及人们对精准医疗的兴趣日益浓厚是推动市场扩张的主要因素。此外，透过製药公司和研究机构的联合研究，下一代标靶治疗药物的开发正在快速进展。

依库珠单抗和利妥昔单抗等单株抗体透过针对特定的免疫成分彻底改变了 MG 治疗，从而实现了更有效的疾病管理。免疫疗法的不断进步增强了我们应对复杂免疫因素的能力，并提供更精确、更有效的治疗选择。

本报告研究了全球重症肌无力治疗市场，并概述了市场状况、药物类别、分销管道和地区的趋势，以及参与市场的公司的竞争动态。

目录

第1章 执行摘要

第2章 市场概况

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • COVID-19 影响分析
  • 乌克兰与俄罗斯衝突的影响
  • 经济概况
  • PESTLE分析

第3章 2019 年至 2032 年全球重症肌无力治疗市场展望

  • 2019 年至 2032 年全球重症肌无力治疗市场预测（按药物类别、价值（十亿美元））
  • 2019 年至 2032 年全球重症肌无力治疗市场预测（按分销管道划分）价值（十亿美元）
  • 2019 年至 2032 年全球重症肌无力治疗市场预测（按地区划分）价值（十亿美元）

第4章 2019 年至 2032 年北美重症肌无力治疗市场展望

第5章 2019 年至 2032 年欧洲重症肌无力治疗市场展望

第6章 亚太地区重症肌无力治疗市场展望，2019-2032 年

第7章 2019 年至 2032 年拉丁美洲重症肌无力治疗市场展望

第8章 中东和非洲重症肌无力治疗市场展望，2019 - 2032 年

第9章 竞争格局

  • 2025 年企业市占率分析
  • 比赛仪表板
  • 公司简介
    • Grifols SA
    • Pfizer, Inc.
    • AbbVie Inc.
    • GSK
    • Novartis AG
    • Alexion Pharmaceutical Inc.
    • F. Hoffman-La Roche Ltd.
    • Bausch Health Companies Inc.
    • Shire plc.
    • Avadel Pharmaceuticals plc.

第 10 章 附录

简介目录

The global myasthenia gravis (MG) treatment market is poised for substantial growth, with projections indicating an 8.2% compound annual growth rate (CAGR). The market size is expected to surge from USD 2.69 billion in 2025 to USD 4.67 billion by 2032. This upward trajectory is fueled by technological advancements in treatment methodologies and rising awareness about MG.

Overview of Myasthenia Gravis and Treatment Approaches

Myasthenia gravis (MG) is a neuromuscular autoimmune disorder that leads to muscle weakness and fatigue due to disrupted communication between nerves and muscles. The primary goal of treatment is to enhance neuromuscular transmission and suppress autoimmune activity. Available therapeutic strategies include acetylcholinesterase inhibitors, immunosuppressive drugs, and innovative monoclonal antibody therapies.

The increasing prevalence of MG, particularly among the aging demographic, and the growing focus on precision medicine are key drivers of market expansion. Moreover, collaborations between pharmaceutical companies and research institutions are fast-tracking the development of next-generation targeted treatments.

Key Market Growth Drivers

1. Breakthroughs in Immunotherapy

  • Monoclonal antibodies, such as eculizumab and rituximab, are revolutionizing MG treatment by targeting specific immune components, leading to more effective disease management.
  • Ongoing advancements in immunotherapy are enhancing the ability to address complex immunological factors, providing more precise and effective treatment options.

2. Increasing Awareness and Early Diagnosis

  • Enhanced diagnostic tools and public health initiatives are facilitating earlier detection of MG, improving patient outcomes.
  • Greater recognition among healthcare professionals and public awareness campaigns are boosting demand for effective treatment solutions.

Emerging Business Opportunities

1. Expansion of Personalized Treatment Strategies

  • Precision medicine is reshaping MG treatment by customizing therapies based on individual genetic profiles. This approach enhances treatment efficacy and minimizes side effects.
  • Advancements in immunogenetics and biotechnology are fostering the development of personalized therapeutic solutions.

2. Innovation in Treatment Modalities

  • Companies exploring new treatment avenues, such as gene therapies and advanced immunomodulators, have the potential to address unmet medical needs and unlock new revenue opportunities.
  • The adoption of next-generation biologics and novel drug formulations is reshaping the competitive Analysisof MG treatment.

Regional Market Insights

1. Europe: A Hub for Advanced MG Treatments

  • Europe leads the market due to its robust healthcare infrastructure and supportive regulatory framework.
  • Cutting-edge diagnostic facilities and specialized neurological care centers are driving rapid adoption of advanced MG treatments.
  • The European Medicines Agency's (EMA) proactive policies bolster investment confidence and accelerate drug development initiatives.

2. South Asia & Pacific: Fastest-Growing Market

  • Rapid population growth, along with an increasing prevalence of MG, is fueling demand for effective treatment solutions in this region.
  • Expanding healthcare access, coupled with rising awareness campaigns, is encouraging early diagnosis and treatment adoption.

Market Challenges and Barriers

1. Regulatory Hurdles

  • Stringent approval processes for new MG drugs can delay market entry, making regulatory compliance a critical challenge for pharmaceutical firms.
  • Companies must navigate complex approval requirements to maintain a competitive edge.

2. Complexity of MG Treatment

  • Due to MG's heterogeneous nature, treatment protocols must be personalized, making standardization difficult.
  • The need for individualized treatment plans increases the complexity of drug development and clinical trials.

Competitive Landscape: Key Industry Players

Several leading pharmaceutical companies are actively engaged in developing and commercializing MG treatments, including:

  • Alexion Pharmaceutical Inc.
  • Grifols SA
  • Avadel Pharmaceuticals plc.
  • Novartis AG
  • Pfizer Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Bausch Health Companies Inc.
  • Shire plc

These companies are investing in research and development (R&D) to introduce next-generation therapies and expand their market presence.

Market Segmentation: Key Categories

1. By Drug Class

  • Cholinesterase Inhibitors
  • Corticosteroids
  • Immunosuppressants
  • Intravenous Immunoglobulin (IVIg)
  • Monoclonal Antibodies

2. By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

3. By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Myasthenia Gravis Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2025
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 3.1. Global Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 3.1.1. Key Highlights
      • 3.1.1.1. Corticosteroids
      • 3.1.1.2. IVIg
      • 3.1.1.3. Monoclonal Antibodies
      • 3.1.1.4. Immunosuppressants
      • 3.1.1.5. Cholinesterase Inhibitors
  • 3.2. Global Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 3.2.1. Key Highlights
      • 3.2.1.1. Hospital Pharmacies
      • 3.2.1.2. Retail Pharmacies
      • 3.2.1.3. Online Pharmacies
  • 3.3. Global Myasthenia Gravis Treatment Market Outlook, by Region, Value (US$ Bn), 2019 - 2032
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 4.1. North America Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 4.1.1. Key Highlights
      • 4.1.1.1. Corticosteroids
      • 4.1.1.2. IVIg
      • 4.1.1.3. Monoclonal Antibodies
      • 4.1.1.4. Immunosuppressants
      • 4.1.1.5. Cholinesterase Inhibitors
  • 4.2. North America Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 4.2.1. Key Highlights
      • 4.2.1.1. Hospital Pharmacies
      • 4.2.1.2. Retail Pharmacies
      • 4.2.1.3. Online Pharmacies
  • 4.3. North America Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 4.3.1. Key Highlights
      • 4.3.1.1. Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 4.3.1.2. Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 4.3.1.3. Canada Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 4.3.1.4. Canada Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 5.1. Europe Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Corticosteroids
      • 5.1.1.2. IVIg
      • 5.1.1.3. Monoclonal Antibodies
      • 5.1.1.4. Immunosuppressants
      • 5.1.1.5. Cholinesterase Inhibitors
  • 5.2. Europe Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Hospital Pharmacies
      • 5.2.1.2. Retail Pharmacies
      • 5.2.1.3. Online Pharmacies
  • 5.3. Europe Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.2. Germany Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.3. U.K. Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.4. U.K. Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.5. France Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.6. France Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.7. Italy Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.8. Italy Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.9. Turkey Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.10. Turkey Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.11. Russia Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.12. Russia Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.13. Rest of Europe Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.14. Rest of Europe Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 6.1. Asia Pacific Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Corticosteroids
      • 6.1.1.2. IVIg
      • 6.1.1.3. Monoclonal Antibodies
      • 6.1.1.4. Immunosuppressants
      • 6.1.1.5. Cholinesterase Inhibitors
  • 6.2. Asia Pacific Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Hospital Pharmacies
      • 6.2.1.2. Retail Pharmacies
      • 6.2.1.3. Online Pharmacies
  • 6.3. Asia Pacific Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.2. China Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.3. Japan Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.4. Japan Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.5. South Korea Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.6. South Korea Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.7. India Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.8. India Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.9. Southeast Asia Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.10. Southeast Asia Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.11. Rest of Asia Pacific Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.12. Rest of Asia Pacific Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 7.1. Latin America Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Corticosteroids
      • 7.1.1.2. IVIg
      • 7.1.1.3. Monoclonal Antibodies
      • 7.1.1.4. Immunosuppressants
      • 7.1.1.5. Cholinesterase Inhibitors
  • 7.2. Latin America Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 7.2.1. Key Highlights
      • 7.2.1.1. Hospital Pharmacies
      • 7.2.1.2. Retail Pharmacies
      • 7.2.1.3. Online Pharmacies
  • 7.3. Latin America Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 7.3.1.2. Brazil Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 7.3.1.3. Mexico Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 7.3.1.4. Mexico Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 7.3.1.5. Argentina Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 7.3.1.6. Argentina Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 7.3.1.7. Rest of Latin America Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 7.3.1.8. Rest of Latin America Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 8.1. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Corticosteroids
      • 8.1.1.2. IVIg
      • 8.1.1.3. Monoclonal Antibodies
      • 8.1.1.4. Immunosuppressants
      • 8.1.1.5. Cholinesterase Inhibitors
  • 8.2. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 8.2.1. Key Highlights
      • 8.2.1.1. Hospital Pharmacies
      • 8.2.1.2. Retail Pharmacies
      • 8.2.1.3. Online Pharmacies
  • 8.3. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.2. GCC Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.3. South Africa Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.4. South Africa Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.5. Egypt Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.6. Egypt Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.7. Nigeria Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.8. Nigeria Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.9. Rest of Middle East & Africa Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.10. Rest of Middle East & Africa Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Market Share Analysis, 2025
  • 9.2. Competitive Dashboard
  • 9.3. Company Profiles
    • 9.3.1. Grifols SA
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Product Portfolio
      • 9.3.1.3. Financial Overview
      • 9.3.1.4. Business Strategies and Development
    • 9.3.2. Pfizer, Inc.
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Product Portfolio
      • 9.3.2.3. Financial Overview
      • 9.3.2.4. Business Strategies and Development
    • 9.3.3. AbbVie Inc.
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Product Portfolio
      • 9.3.3.3. Financial Overview
      • 9.3.3.4. Business Strategies and Development
    • 9.3.4. GSK
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Product Portfolio
      • 9.3.4.3. Financial Overview
      • 9.3.4.4. Business Strategies and Development
    • 9.3.5. Novartis AG
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Product Portfolio
      • 9.3.5.3. Financial Overview
      • 9.3.5.4. Business Strategies and Development
    • 9.3.6. Alexion Pharmaceutical Inc.
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Product Portfolio
      • 9.3.6.3. Financial Overview
      • 9.3.6.4. Business Strategies and Development
    • 9.3.7. F. Hoffman-La Roche Ltd.
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Product Portfolio
      • 9.3.7.3. Financial Overview
      • 9.3.7.4. Business Strategies and Development
    • 9.3.8. Bausch Health Companies Inc.
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Product Portfolio
      • 9.3.8.3. Financial Overview
      • 9.3.8.4. Business Strategies and Development
    • 9.3.9. Shire plc.
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Product Portfolio
      • 9.3.9.3. Financial Overview
      • 9.3.9.4. Business Strategies and Development
    • 9.3.10. Avadel Pharmaceuticals plc.
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Product Portfolio
      • 9.3.10.3. Financial Overview
      • 9.3.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations